IL1B and non-small cell lung carcinoma: Furthermore, in a post hoc analysis of the phase 3 Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS; NCT01327846) that investigated canakinumab for the secondary prevention of major cardiovascular events, significant reductions in both lung cancer incidence and mortality were observed in patients treated with canakinumab in a dose-dependent manner, building the rationale to explore IL-1β as a therapeutic target in patients with NSCLC.18